Evidence map›Paper›PMID 42365188›Full record

ArticleDrug delivery and translational research2026

Redispersible nanoalum-adjuvanted hepatitis B vaccine microneedles with enhanced immunogenicity.

Miju Kim, Hyemi Kim, Seojin Byun, Min-Ju Kwon, Seung-Ki Baek, Chaiwon Kim, Tae-Hyun Kim, Jae Myun Lee, Kihyuck Kwak, Jung-Hwan Park

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miju Kim *Department of BioNano Technology, Gachon University, 1342 Seongnam-daero, Sujeong- gu, Seongnam-si, 13120, Gyeonggi-do, Republic of Korea.
Hyemi Kim *Department of Microbiology and Immunology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Seojin Byun *Department of BioNano Technology, Gachon University, 1342 Seongnam-daero, Sujeong- gu, Seongnam-si, 13120, Gyeonggi-do, Republic of Korea.
Min-Ju KwonDepartment of BioNano Technology, Gachon University, 1342 Seongnam-daero, Sujeong- gu, Seongnam-si, 13120, Gyeonggi-do, Republic of Korea.
Seung-Ki BaekR&D Centre, QuadMedicine Inc, Sagimakgol-ro, 45beon-gil, Jungwon-gu, Seongnam-si, 13209, Gyeonggi-do, Republic of Korea.
Chaiwon KimDepartment of Microbiology and Immunology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Tae-Hyun KimBioCMC R&D center, Life Science, LG Chem, Ltd, Gangseo-gu, Seoul, 07795, Republic of Korea.
Jae Myun LeeDepartment of Microbiology and Immunology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Kihyuck KwakDepartment of Microbiology and Immunology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. kihyuckkwak@yuhs.ac.
Jung-Hwan ParkDepartment of BioNano Technology, Gachon University, 1342 Seongnam-daero, Sujeong- gu, Seongnam-si, 13120, Gyeonggi-do, Republic of Korea. pa90201@gachon.ac.kr.ORCID http://orcid.org/0000-0003-4684-7568

Funding

Gachon University 2023.(GCU-202401050001)Korea Health Industry Development Institute RS-2025-02215878
6 · The paper itself

Abstract

Nanoalum has been widely investigated as an advanced aluminum-based adjuvant; however, its performance in solid vaccine formulations remains poorly understood because administration depends on reconstitution after storage and delivery. Here, a hepatitis B surface antigen (HBsAg) vaccine was formulated with nanoalum, freeze-dried, and delivered using a powder-attached microneedle array patch (P-MAP). Formulations were screened based on redispersion in PBS after lyophilization to identify a lead composition (HBsAg: Alhydrogel: PAA: Trehalose = 1:5:5:50, w/w/w/w; F12), and the effects of preparation pH (7.4 vs. 5.6) were evaluated. The optimized formulation maintained a nanoscale dispersed state after PBS reconstitution (< 250 nm), whereas PEG-substituted and PAA-free formulations showed severe aggregation (> 2 μm). When administered as liquid intradermal injections, preparation pH produced minimal differences in immune responses. In contrast, clear divergence emerged following freeze-drying and P-MAP delivery. The pH 5.6 formulation (G9) generated the highest IFN-γ ELISpot response among all P-MAP groups while maintaining strong HBsAg-specific IgG responses and an increased IgG2a/IgG1 tendency. The PAA-free formulation (G10), which exhibited poor redispersion after reconstitution, produced reduced and more variable antibody responses. Notably, formulations displaying nanoscale redispersion consistently outperformed aggregated formulations in both humoral and cellular immune responses. These findings demonstrate that post-lyophilization redispersion is a critical quality attribute for nanoalum-containing solid vaccine formulations and that formulation conditions governing redispersion can substantially influence immune outcomes following P-MAP delivery.

Indexed as

Aluminum adjuvantHepatitis B vaccineIntradermal vaccinationLyophilized vaccineNanoalumPowder-attached microneedle patchRedispersibility

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.